Terminated PHASE2 INTERVENTIONAL 1-arm NCT02030574

Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin

BrUOG 300: Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin

Sponsor: Brown University

Conditions Bladder Cancer Invasive Bladder Cancer

Interventions Gemcitabine and fractionated cisplatin (combination treatment)

Updated 12 times since 2017 Last updated: Jul 25, 2016 Started: Jul 31, 2014 Primary completion: Jun 30, 2015 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study is being closed to accrual secondary to low accrual and an interest in opening up a different trial.

Other terminated trials from Brown University

See all terminations from Brown University

Other Bladder Cancer trials with similar outcome

Browse all Bladder Cancer trials

This PHASE2 trial investigates Bladder Cancer and Invasive Bladder Cancer and is currently terminated or withdrawn. Brown University leads this study, which shows 12 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

12 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2
Dec 2021 — Dec 2022 [monthly]

Terminated PHASE2

▶ Show 7 earlier versions

Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2
Nov 2020 — Jan 2021 [monthly]

Terminated PHASE2
Jun 2018 — Nov 2020 [monthly]

Terminated PHASE2
May 2018 — Jun 2018 [monthly]

Terminated PHASE2
Aug 2017 — May 2018 [monthly]

Terminated PHASE2
Feb 2017 — Aug 2017 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Jul 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Brown University
Lifespan

Data source: Brown University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Providence, United States